^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ODN2395

    i
    Other names: ODN2395, oligodeoxynucleotide 2395, ODN-2395, ODN 2395
    Associations

    News

    Trials
    Company:
    TriSalus Life Sci
    Drug class:
    TLR9 agonist
    Related drugs:
    Associations

    News

    Trials
    over2years
    Regional infusion of a class C TLR9 agonist enhances liver tumor microenvironment reprogramming and MDSC reduction to improve responsiveness to systemic checkpoint inhibition. (PubMed, Cancer Gene Ther)
    Further, PBMC-derived human MDSCs express TLR9, and treatment with class C TLR9 agonists (ODN2395 and SD101) reduced the expansion of MDSC population. Regional TLR9 agonist infusion along with systemic anti-PD-1 therapy improved control of LM. With effective delivery, TLR9 agonists have the potential to favorably reprogram the liver TME through reduction of MDSCs and favorable macrophage polarization, which may improve responsiveness to systemic CPI therapy.
    Journal • Checkpoint inhibition
    |
    IL6 (Interleukin 6)
    |
    nelitolimod (SD-101) • ODN2395